Selection criteria
Randomised controlled trials of any therapy that has been shown to significantly lower homocysteine levels conducted in people with functioning kidney transplants. Studies were to be included if they compared homocysteine lowering therapy with placebo or usual care, or compare higher versus lower doses of homocysteine lowering therapy.
Data collection and analysis
Two authors independently assessed study quality and extracted data. Results were to be expressed as the risk ratio (RR) for dichotomous outcomes or mean difference (MD) for continuous outcomes with 95% confidence intervals (CI). Data was to be pooled using the random effects model.
Main results
The literature search yielded 359 reports of which only one study was identified that met our inclusion criteria and reported relevant clinical endpoints. This study randomised 4110 adult participants with a functioning kidney transplant and elevated homocysteine levels to folic acid plus high dose B multivitamins or low dose multivitamins who were followed for a mean 4.0 years. Despite effectively lowering homocysteine levels) in homocysteine levels at follow-up (MD -4.40 µmol/L, 95% CI -5.98 to -2.82) there was no evidence the intervention impacted on any of the outcomes reported including cardiovascular mortality (RR 0.91, 95% CI 0.69 to 1.20), allcause mortality (RR 1.04, 95% CI 0.88 to 1.22), myocardial infarction (RR 1.02, 95% CI 0.77 to 1.35), stroke (RR 1.08, 95% CI 0.69 to 1.71), commencement of renal replacement therapy (RR 1.12, 95% CI 0.91 to 1.37) or all reported adverse events (RR 1.02, 95% CI 0.87 to 1.20). There was no evidence the intervention impacted on the primary endpoint of the study, a cardiovascular event composite (RR 0.99, 95% CI 0.85 to 1.15). The study was of high quality.
Authors' conclusions
There is no current evidence to support the use of homocysteine lowering therapy for cardiovascular disease prevention in kidney transplant recipients.
P L A I N L A N G U A G E S U M M A R Y

Interventions for lowering plasma homocysteine levels in kidney transplant recipients
People with high homocysteine levels have higher rates of cardiovascular disease than those with homocysteine levels within the normal range. Kidney transplant recipients have proportionately more cardiovascular disease events than the general population. The aim of this review was to determine if homocysteine lowering therapies effectively reduce cardiovascular event rates in kidney transplant recipients. A single study was identified that randomised 4110 adult participants with a functioning kidney transplant to homocysteine lowering with folic acid and high dose multivitamins or to low dose multivitamins and followed them for an average of four years. Despite effectively lowering homocysteine levels, there was no evidence of benefit for any of a range of cardiovascular events. Similarly there was no evidence of harm.
B A C K G R O U N D Description of the condition
Kidney transplantation is the treatment of choice for end-stage kidney disease (ESKD), producing a life changing improvement in quality of life and adding approximately 10 years to the life expectancy of patients with ESKD on the transplant waiting list (NIH 2007) . Despite the many developments in kidney transplantation over the last 50 years, recipients of kidney transplants continue to have an excess mortality and morbidity compared with the general population (NIH 2007). Cardiovascular disease (CVD) is a leading cause of death and late graft loss in kidney transplant recipients (Kasiske 1996; NIH 2007) . In a recent report of a RCT in kidney transplant recipients with 20 years follow-up, cardiovascular deaths accounted for 53% of the total death rate (Gallagher 2009). Similar findings were reported by the large Assessment of Lescol in Renal Transplantation (ALERT) study (ALERT Study 2003 ). An observational cohort study has also reported the cumulative incidence of CVD 15 years after transplantation to be 23% for coronary artery disease, 15% for cerebrovascular disease and 15% for peripheral vascular disease (PVD) (Kasiske 1996) . The overall risk of CVD following kidney transplantation is five times higher than that of the general population (Kasiske 1996).
Description of the intervention
In untreated classical homocysteinuria, a homozygous genetic disorder of C677T MTHFR resulting in very high levels of plasma homocysteine (100 to 400 µmol/L), death at a young age from venous thromboembolism and malignant arterial disease is frequently observed. Moreover, long-term treatments that lower homocysteine levels have been extremely effective in reducing the potentially life threatening vascular risk of these patients (Yap 2003) . In addition, in the general population and Kidney transplant recipients high homocysteine levels has been shown to be an independent risk factor for CVD including stroke, myocardial in- 
How the intervention might work
Homocysteine is thought to play an active role in the pathogenesis of atherosclerosis by damaging the endothelium and promoting intra-arterial and venous thrombosis. There is strong experimental evidence that hyperhomocysteinaemia produces endothelial cell injury and proliferation of medial smooth muscle cells (Lang 2000; Lentz 1996; McCully 1996; Starkebaum 1986). In addition homocysteine has been found to enhance the activity of and increase the synthesis of clotting factors (D'Angelo 1997; Lentz 1991).
Why it is important to do this review
The role of homocysteine lowering in kidney transplant recipients has not been established. The kidney transplant recipient group may be the ideal group to test the homocysteine hypothesis as they have a high cardiovascular event rate (Kasiske 1996) and unlike the ESKD population, can achieve normal homocysteine levels with folic acid, vitamin B 12 , and vitamin B 6 treatment (Beaulieu 1999). The harms of homocysteine lowering interventions have also not been established. Whilst it is generally believed that folic acid, vitamin B 6 and B 12 supplementation are safe, there are concerns that high folic acid levels may lead to increased cancer risk (Hubner 2007) . This is of particular concern in the kidney transplant recipient group as they have higher absolute rates of malignancy than the general population. Thus even a small increase in relative risk of cancer may outweigh any potential benefits. Efforts to reduce cardiovascular risk in kidney transplant recipients are attractive because of the large potential benefit of treatment. The European clinical guidelines (EBPG 2002) state the need for more research to be conducted as there is no evidence that reduction of homocysteine levels decreases the incidence of CVD in kidney transplant recipients. This meta-analysis aims to assess the benefits and harms of homocysteine lowering therapy in kidney transplant recipients in order to guide decision making and improve outcomes for this patient population.
O B J E C T I V E S
To evaluate the effects of established homocysteine lowering therapy on cardiovascular mortality in patients with functioning kidney transplants.
M E T H O D S
Criteria for considering studies for this review Types of studies 1. Randomised controlled trials (RCTs) and quasi-RCTs (allocation to treatment was obtained by alteration, use of alternate medical records, date of birth or other predictable methods).
2. Including a minimum of 100 patient-years follow-up (to reduce the risk of reporting or publication bias). Studies with a sequential or cross-over design were excluded.
Types of participants
All patients (adults and children) with a functioning kidney transplant defined as a kidney transplant in situ with no requirement for maintenance dialysis, or as defined by study authors.
Types of interventions
Studies randomising patients to any therapy which has been shown to significantly lower homocysteine levels were included (e.g. folic acid, vitamin B 6 and vitamin B 12 ). Studies of regimens in which a major mechanism of action is not thought to be homocysteine lowering will be excluded (e.g. simvastatin plus folic acid). Comparisons to be investigated were as follows.
• Homocysteine lowering therapy versus placebo or usual care
• Higher versus lower dose homocysteine lowering therapy • Any schedule of treatment • Any route of treatment.
Types of outcome measures
Primary outcomes
• Cardiovascular mortality 2. Experts in the field were contacted for additional studies.
Data collection and analysis
Selection of studies
Two authors independently assessed each reference for eligibility. Language was not an exclusion criterion. Disagreement regarding inclusion in the review was resolved by consensus among three authors.
Data extraction and management
Data extraction was performed independently by two authors using a standardised data form, who independently entered the data into RevMan 5. Where more than one publication of the study exists, the publications with the most complete data will be included. Where relevant outcomes were only published in earlier versions, these data were to be used. Any discrepancy between published versions was to be noted. The original author was to be contacted via written correspondence for any further information or clarification of unclear data. Disagreements were to be resolved by consensus among three authors.
Assessment of risk of bias in included studies
Two authors were to independently assess the following items using the risk of bias assessment tool (Higgins 2011) (see Appendix 2).
• Was there adequate sequence generation (selection bias)?
• Was allocation adequately concealed (selection bias)?
• Was knowledge of the allocated interventions adequately prevented during the study (detection bias)?
• Participants and personnel • Outcome assessors • Were incomplete outcome data adequately addressed (attrition bias)?
• Are reports of the study free of suggestion of selective outcome reporting (reporting bias)?
• Was the study apparently free of other problems that could put it at a risk of bias?
Measures of treatment effect
For dichotomous outcomes (all-cause mortality, MI, coronary revascularization, cardiovascular death, stroke, cerebrovascular revascularization, lower limb amputation, DVT, PE, commencement of RRT), results were to be expressed as risk ratio (RR) with 95% confidence intervals (CI). If a significant risk reduction was found, the absolute risk reduction with therapy was to be calculated in relation to the absolute risk found in the placebo/comparator group.
Dealing with missing data
Where outcomes sought were reported in insufficient detail to allow meta-analysis and further information was not forthcoming from triallists, these outcomes were to be tabulated and assessed with descriptive techniques and where possible the risk difference (RD) with 95% CI was to be calculated. If sufficient RCTs were identified, an attempt was to be made to evaluate the risk of publication bias using a funnel plot. Attrition bias was to be assessed using the loss/event ratio.
Assessment of heterogeneity
Heterogeneity was to be analysed using a Chi 2 test on N-1 degrees of freedom, with an alpha of 0.05 used for statistical significance and with the I 2 test (Higgins 2003). I 2 values of 25%, 50% and 75% were taken to correspond to low, medium and high levels of heterogeneity.
Assessment of reporting biases
The intention was that the risk of publication bias was to be evaluated using a funnel plot. Attrition bias was to be assessed using the loss/event ratio.
Data synthesis
The intention was that data was to be pooled using the randomeffects model but the fixed-effect model would also be analysed to ensure robustness of the model chosen and susceptibility to outliers.
Subgroup analysis and investigation of heterogeneity
Subgroup analyses were to be conducted to explore possible sources of heterogeneity. Heterogeneity was to be analysed using the Cochran Q test on N-1 degrees of freedom, with P < 0.05 used to denote statistical significance, and the I 2 test (with uncertainty intervals). Subgroup analyses were to be conducted according to the following characteristics.
• Gender • Adults and children • History of cardiac disease or diabetes mellitus • Prior vitamin supplementation • Concurrent vitamin supplementation • Concomitant medications (e.g. aspirin)
• Mandatory grain fortification in the country study conducted
• Baseline homocysteine level (≤ upper limit normal (ULN) versus > ULN).
We intended to conduct a subgroup analysis if possible using these characteristics. Plausible explanations for variations in treatment effect were to be explored using subgroup analyses based on study quality and length of follow-up.
Sensitivity analysis
Sensitivity analyses were to be conducted to ensure conclusions were robust to decisions made during the review process such as inclusion criteria and imputing of missing data. Sensitivity analyses were also to be conducted to assess the influence of methodological quality.
R E S U L T S Description of studies
Results of the search
The literature search yielded a total of 359 records (Figure 1 ). Of these, 44 were reviewed in full text. One study (13 reports) was identified that met our inclusion criteria (FAVORIT Study 2006). 
Outcomes
The primary outcome was a composite of cardiovascular disease (cardiovascular death, MI, resuscitated sudden death, stroke, coronary artery revascularization, lower extremity revascularization, above-ankle amputation for severe arterial disease, carotid endarterectomy or angioplasty, abdominal aortic aneurysm repair or renal artery revascularization). Patients commencing dialysis continued on study treatment until they reached a primary endpoint whereupon study medication was ceased.
Excluded studies
After full text review we excluded 31 records (19 studies). The reasons for exclusion were: wrong study design (5); wrong intervention (6) or < 100 patient-years. See Characteristics of excluded studies.
Risk of bias in included studies
The identified study has an overall low risk of bias (Risk of bias in included studies).
Effects of interventions
Meta-analysis was not applied as only a single eligible study was identified (FAVORIT Study 2006). FAVORIT Study 2006 found that, based on a subgroup of 143 participants, high dose folic acid and B group vitamins significantly lowered homocysteine levels (Analysis 1.1 (143 participants): -4.40 µmol/L, 95% CI -5.98 to -2.82). Despite effectively lowering homocysteine levels there was no evidence the intervention impacted on any of the outcomes for this review.
• Cardiovascular mortality (Analysis 1.2 (4110 participants): RR 0.91, 95% CI 0.69 to 1.20)
• All-cause mortality (Analysis 1.3 (4110 participants): RR 1.04, 95% CI 0.88 to 1.22)
• MI (Analysis 1.4 (4110 participants): RR 1.02, 95% CI 0.77 to 1.35)
• Coronary revascularization (Analysis 1.5 (4110 participants): RR 0.93, 95% CI 0.73 to 1.19)
• Stroke (Analysis 1.6 (4110 participants): RR 1.08, 95% CI 0.69 to 1.71)
• Cerebrovascular revascularization (defined in the FAVORIT Study 2006 as carotid endarterectomy or angioplasty) (Analysis 1.7 (4110 participants): RR 1.11, 95% CI 0.45 to 2.73)
• Commencement of RRT (defined in the FAVORIT Study 2006 as dialysis-dependent kidney failure) (Analysis 1.8 (4110 participants): RR 1.12, 95% CI 0.91 to 1.37)
• Adverse gastrointestinal events (Analysis 1.9 (4110 participants): RR 1.06, 95% CI 0.83 to 1.36)
• All reported adverse events (Analysis 1.10 (4110 participants): RR 1.02, 95% CI 0.87 to 1.20).
No data were reported in the FAVORIT Study 2006 for change in kidney function, deep vein thrombosis and PE, lower limb amputation per se (although it was included in a PVD composite), adverse dermatological events, adverse neurological events or adverse malignant events. There was no evidence the intervention impacted on the primary endpoint of the FAVORIT Study 2006, a cardiovascular event composite (RR 0.99, 95% CI 0.85 to 1.15), nor on any of the secondary endpoints not mentioned above including resuscitated sudden death (RR 0.80, 95% CI 0.32 to 2.02), PVD defined as lower extremity revascularization or amputation above the ankle for severe arterial disease (RR 1.17, 95% CI 0.81 to 1.67), abdominal aortic aneurysm repair (RR 0.60, 95% CI 0.14 to 2.50) and renal artery revascularization (RR 1.28, 95% CI 0.48 to 3.44).
D I S C U S S I O N
Summary of main results
This review identified only one completed study that met our inclusion criteria for examining the effectiveness of homocysteine lowering in kidney transplant recipients. In this study, there was no evidence that homocysteine lowering had an effect on any of the assessed cardiovascular outcomes, including cardiovascular mortality, MI, and stroke, other clinical outcomes, including all-cause mortality, requirement for dialysis treatment or access thrombosis, nor on adverse effects.
Overall completeness and applicability of evidence
Beyond kidney transplantation, the impact of homocysteine has been studied in people with other categories of kidney disease. A systematic review performed by our group examined the impact of folic acid-based homocysteine lowering in people with any type of kidney disease categorised as ESKD, CKD and functioning kidney transplantation (Jardine 2012). Eleven studies were identified reporting 3045 cardiovascular events among 10,863 participants of which the FAVORIT Study 2006 contributed 4110 participants. There was no evidence homocysteine lowering reduced the primary cardiovascular composite endpoint either overall (RR 0.97, 95% CI 0.92 to 1.03) nor in any of three defined categories of kidney disease (P = 0.785). This data is consistent with studies in the general population, where folic acid based homocysteine lowering has also not been found to prevent cardiovascular events in large RCTs. The B-Vitamin Treatment Trialists' Collaboration has performed two individual patient level data analyses of larger studies randomising participants to folate-containing B group vitamins (Clarke 2010; Vollset 2013) although neither were able to include the FAVORIT Study 2006. The first primarily analysed the impact on the incidence of vascular disease in 37,485 participants in eight studies while the second assessed cancer incidence in 49,621 participants in 13 studies. Over a median of five years of treatment, folate-containing B group vitamin supplementation had no impact on major vascular events (RR 1.01, 95% CI 0.97 to 1.05) or mortality (RR 1.02, 95% CI 0.97 to 1.08) despite an average 25% reduction in homocysteine levels. There was no evidence of heterogeneity in subgroup analyses comparing the impact of the intervention according to serum creatinine (< 80, 80 to 94 and ≥ 95 µmol/L). Similarly there was no impact on cancer incidence over average five years treatment duration (RR 1.06, 95% CI 0.99 to 1.13). In combination these studies appear to have effectively excluded any beneficial cardiovascular effect of homocysteine lowering therapy in the general population and in people with kidney disease.
Quality of the evidence
The included study (FAVORIT Study 2006) was of assessed as high quality.
Potential biases in the review process
We specifically included only RCTs with a minimum of 100 patient-years follow-up in our inclusion criteria to reduce the risk of reporting or publication bias that may be associated with small studies (Egger 1997). To investigate the impact of the 100 patient-year criteria on our results, we modified our inclusion criteria to include studies of any follow-up duration that met all other search criteria in a sensitivity analysis. 6 and vitamin B 12 and found no significant difference in homocysteine levels between the groups. Some of these studies did not report baseline and achieved homocysteine levels for each group, which prevented their combination using meta-analysis (Bostom 1997; Perez 2004; Xu 2005a). Marcucci 2002 reported a significant decrease in carotid intima-media thickness (cIMT) in the treatment arm (0.95 ± 0.20 mm versus 0.64 ± 0.17 mm; P < 0.0001) and an increase in cIMT in the placebo group (0.71 ± 0.16 mm versus 0.87 ± 0.19 mm; P < 0.05). Xu 2005a found a significant increase in endothelium dependent and independent vasodilatation response following the intervention (12.2% ± 4.6% versus 8.8% ± 5.2%, t = 2.9, P < 0/01 and 17.6% ± 3.9% versus 12.2% ± 4.7%, t = 3.4, P < 0.01) and there were no significant changes observed in controls. None of these RCTs reported the defined clinical events and therefore could not contribute to our planned analyses. Therefore, regardless of the patient-year parameter in our inclusion criteria, we were unable to find more than one completed study that evaluated the effect of homocysteine lowering therapy on cardiovascular end points rather than surrogate markers for cardiovascular disease.
Agreements and disagreements with other studies or reviews
The KDIGO 2009 and CARI 2012 for the care of people with functioning kidney transplants do not comment on folic acid or B vitamin supplementation. The UK Renal Association suggests offering folic acid and B group vitamin supplementation to patients with kidney disease considered at risk of nutritional deficiency but notes insufficient evidence to recommend supraphysiological supplementation for vascular risk modification (The Renal Association 2010). The guidelines noted the (then) ongoing FAVORIT Study 2006 would supply evidence for people with functioning kidney transplants.
A U T H O R S ' C O N C L U S I O N S Implications for practice
Implications for research
Research focusing on mechanisms to reduce cardiovascular disease events in kidney transplant recipients is warranted.
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C H A R A C T E R I S T I C S O F S T U D I E S Characteristics of included studies [ordered by study ID]
FAVORIT Study 2006
Methods
• • Exclusion criteria: presence of cancer, end-stage congestive heart failure, liver, or pulmonary disease, progressive human immunodeficiency virus or other chronic wasting illness, which in the opinion of the study physician would limit the life expectancy of the patient to less than 2 years or prevent evaluation of recurrent or de novo CVD; other conditions that prevent reliable participation in the study (refractory depression, severe cognitive impairment, or alcoholism or other substance abuse); history of solid organ transplant other than the kidney or pancreas; pregnant or lactating women or women of childbearing potential not practicing birth control; < 3 months post-acute MI or stroke, or < 3 months post-coronary artery, renal artery, or lower extremity artery percutaneous transluminal coronary angioplasty, or lower extremity amputation; less than 6 months post-coronary artery bypass graft surgery, abdominal aortic aneurysm; participation in another clinical study specifically involving CVD risk factor management 
A P P E N D I C E S Appendix 1. Electronic search strategies
Databases Search terms
